Looking to the Future: Treatment Paths for Relapsed/Refractory DLBCL
Plus: How Academic & Community Hospitals Work Together for You
For people facing relapsed or refractory DLBCL, the path forward can feel uncertain and overwhelming trying to weigh treatment options.
That’s why this program brings together Dr. Joshua Brody from Mount Sinai and Dr. Amir Steinberg from Westchester Medical Center, two lymphoma specialists who coordinate closely across academic and community settings. Moderated by The Patient Story’s own founder and DLBCL survivor, Stephanie Chuang, they’ll share how new therapies are changing the landscape and how working together across systems helps ensure patients have access to the most up-to-date treatments and support.
Topics:
What relapsed/refractory DLBCL means for patients
Latest treatment advances and what they could mean for care
How academic and community oncologists collaborate on patient treatment
Clinical trial opportunities and why they matter
Practical tips for patients to advocate for themselves and ask the right questions
What the future may hold for people living with DLBCL
Thank you to Genmab and AbbVie for their support of our patient education program. The Patient Story retains full editorial control over all content.
Register for this informative program then invite a Friend or Care Partner.
